Hemopure ® , a newly developed hemoglobin-based oxygen carrying solution , is currently undergoing phase II clinical trials in elective surgical patients. Hemopure is a glutaraldehyde-polymerized, stroma free, bovine hemoglobin solution that is administered intravenously. Patients infused with this solution showed highly increased concentrations of plasma hemoglobin as expected. Since plasma hemoglobin may affect the accuracy of many instruments and assays [1] , we studied the effect of Hemopure on the performance of commonly used coagulation analyzers. This study was conducted on seven different instrument models from four manufacturers and covered four types of methodologies that are widely available. The assays targeted were prothrombin time (PT) and activated partial thromboplastin time (aPTT). We used a "paired-difference" method [2] to prepare the samples for this interference study. The stock solution consisted of a pool of plasma from healthy human donors. We added increasing amounts of Hemopure (5%, 10%, 20%, 30%, and 50%) to the pool. The plasma hemoglobin concentrations ranged from 6.5 g/L to 65 g/L. For each Hemopure-containing sample, a control was prepared by diluting the same plasma pool with an equivalent amount of saline. A total of 10 hospital laboratories participated in this study. The samples were analyzed for PT and aPTT on the following analyzers: MLA 700, MLA 1000, MLA 1600 (Medical Laboratory Automation); Diagnostica Stago ST4, Diagnostica Stago STA (American Bioproducts); ACL 1000 (Instrumentation Laboratory); and a fibrometer (Becton Dickinson).
The results obtained on the samples containing Hemopure were compared against the results obtained on the respective controls, and percent differences were calculated (Table 1 ). An assay was considered to be unaffected by Hemopure as long as the differences did not exceed 10%. Optical methods of clot detection (MLA 700, MLA 1000, MLA 1600) were not able to detect clots at Hemopure Ͼ13 g/L for both PT and aPTT. Hemopure Ͻ65 g/L did not affect PTs determined by electromagnetic (Diagnostica Stago ST4 and Diagnostica Stago STA), lightscatter (ACL 1000), and mechanical (fibrometer) methods. aPTTs could also be accurately determined on the fibrometer and the Diagnostica Stago ST4 at Hemopure Յ65 g/L. For the Diagnostica Stago STA, 39 g/L Hemopure interfered. Thus optical methods of clot detection were more susceptible to interference from Hemopure than other methods.
A system was put into place at each facility where samples submitted to the laboratory were clearly identified as being study samples. The laboratory determined the plasma hemoglobin concentration before analysis. If more than one methodology were available, samples were routed to the instrument that showed the least interference from Hemopure at the measured plasma hemoglobin. This simple procedure allowed for the collection of accurate data in support of both patient management and clinical trial results.
Understanding the effect of oxygen carriers on routine clinical assays is important for patient care. Several manufacturers of hemoglobin-based oxygen carrying solutions are now closer to the start of phase III clinical trials. Increasing numbers of laboratories will be faced with more of these samples that appear to be hemolyzed. It is imperative to identify analytical methods that can provide accurate results for these samples. Coagulation instruments that are based on electromagnetic, mechanical, and light-scattering methods avoid the problems seen with optical methods. During this evaluation, we found that most laboratories have alternatives to optical methods, thus allowing analysis of Hemopure-containing samples. 
